Document is current

Article History

Received: 10 August 2023

Accepted: 5 October 2023

First Online: 8 November 2023

Declarations

:

: DMB: Honoraria from Daiichi Sankyo, Novartis, Merck Sharp & Dohme, Janssen, Pfizer, and Angelini; meeting/travel grants from Novartis, Merck Sharp & Dohme, LEO Farmacêuticos, Ipsen, Janssen; (all outside the submitted work); RC: Speaker honoraria from Boehringer-Ingelheim, Janssen and AstraZeneca; travel grants from Pfizer and AstraZeneca (all outside the submitted work); currently a Novartis employee and Novartis stocks ownership (not at the time this work has been conceived); DE: Research Grant—Novartis (ESMO Fellowship 2018–2019); currently a F. Hoffmann-La Roche Ltd employee and F. Hoffmann-La Roche Ltd stocks ownership (not at the time this work has been conceived); UD: Institutional financial support from ESMO for contribution in biostatistics; Honorarium as Member of the Tumor Agnostic Evidence Generation working Group of Roche (all outside the submitted work); SEA: Institutional grants from Roche/Genentech, AstraZeneca, and Pfizer (all outside of the submitted work) and from Novartis during the conduct of the study; SLE: GSK stock ownership (outside the submitted work). MI: Currently a Novartis employee; MPG: Board Member (Scientific Board) from Oncolytics, consultant (honoraria) from AstraZeneca, Camel-IDS/Precirix, Gilead, Immunomedics, Lilly, Menarini, MSD, Novartis, Odonate, Pfizer, Roche-Genentech, Seattle Genetics, Immutep, Seagen, NBE Therapeutics, and Frame Therapeutics, and institutional research grants from AstraZeneca, Immunomedics, Lilly, Menarini, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, and Synthon (all outside the submitted work); AMA: Institutional Research Support from GSK, Daiichi, Novartis, Merck, Pfizer, AbbVie, Eli Lilly, NIH, DOD (all outside the submitted work); ASK: institutional grant from Roche and advisory board from Novartis, Astra Zeneca, MDS, Roche, Pfizer and ELI LILLY DANMARK A/S (all outside the submitted work); JL: AstraZeneca and GSK (honoraria/advisory board); EdA: Honoraria and/or advisory board from Roche/GNE, Novartis, SeaGen, Zodiac, Libbs, Lylli, Astra Zeneca and Pierre Fabre. Travel grants from Roche/GNE and Astra Zeneca. Institutional research grant from Roche/GNE, and Astra-Zeneca (all outside the submitted work). GSK/Novartis provided funding for the conduct of ALTTO. MK, VD, CA, MV, and SC have no conflicts to declare.

: Participating Medical Centers’ Institutional Review Boards (or Ethics Committees) approved the study.

: All patients provided written informed consent prior to study entry.